BRPI0924121A2 - compostos antivirais heterocíclicos - Google Patents
compostos antivirais heterocíclicosInfo
- Publication number
- BRPI0924121A2 BRPI0924121A2 BRPI0924121A BRPI0924121A BRPI0924121A2 BR PI0924121 A2 BRPI0924121 A2 BR PI0924121A2 BR PI0924121 A BRPI0924121 A BR PI0924121A BR PI0924121 A BRPI0924121 A BR PI0924121A BR PI0924121 A2 BRPI0924121 A2 BR PI0924121A2
- Authority
- BR
- Brazil
- Prior art keywords
- antiviral compounds
- heterocyclic antiviral
- heterocyclic
- compounds
- antiviral
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13998208P | 2008-12-22 | 2008-12-22 | |
| US15644209P | 2009-02-27 | 2009-02-27 | |
| PCT/EP2009/067028 WO2010072598A1 (en) | 2008-12-22 | 2009-12-14 | Heterocyclic antiviral compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0924121A2 true BRPI0924121A2 (pt) | 2019-09-24 |
Family
ID=41559516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0924121A BRPI0924121A2 (pt) | 2008-12-22 | 2009-12-14 | compostos antivirais heterocíclicos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8178547B2 (pt) |
| EP (1) | EP2379534A1 (pt) |
| JP (1) | JP2012513434A (pt) |
| KR (1) | KR20110094352A (pt) |
| CN (1) | CN102256968A (pt) |
| AR (1) | AR074819A1 (pt) |
| AU (1) | AU2009331660A1 (pt) |
| BR (1) | BRPI0924121A2 (pt) |
| CA (1) | CA2745865A1 (pt) |
| IL (1) | IL213102A0 (pt) |
| MX (1) | MX2011006647A (pt) |
| SG (1) | SG172778A1 (pt) |
| TW (1) | TW201034671A (pt) |
| WO (1) | WO2010072598A1 (pt) |
| ZA (1) | ZA201104362B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10752611B2 (en) | 2009-02-27 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| SG174214A1 (en) * | 2009-03-25 | 2011-10-28 | Abbott Lab | Antiviral compounds and uses thereof |
| CA2768924A1 (en) * | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CN102639504A (zh) * | 2009-11-21 | 2012-08-15 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| JP5788404B2 (ja) | 2009-12-11 | 2015-09-30 | アウトイフオンイ トヘラペウトイクス リミテッド | イミダゾリジンジオン誘導体 |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| EP2649066B1 (en) | 2010-12-06 | 2015-10-21 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| US9193704B2 (en) | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
| AU2012349847B2 (en) * | 2011-12-06 | 2017-02-16 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
| US9422252B2 (en) | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
| EP2852588B8 (en) | 2012-05-22 | 2018-01-10 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
| WO2015017382A1 (en) * | 2013-07-29 | 2015-02-05 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| ES2824119T3 (es) | 2015-05-18 | 2021-05-11 | Shenyang Sinochem Agrochemicals R & D Co Ltd | Compuestos de pirazol sustituidos que contienen pirimidina, y método de preparación y uso de los mismos como pesticidas |
| EP3719015A4 (en) | 2017-11-29 | 2021-04-21 | Shenyang Sinochem Agrochemicals R & D Co., Ltd. | SUBSTITUTED PYRIMIDINE COMPOUND AND MANUFACTURING METHOD FOR ITS AND USES THEREOF |
| CN112430177B (zh) * | 2019-08-26 | 2023-08-25 | 凯特立斯（深圳）科技有限公司 | 一种孟鲁司特钠中间体的合成方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5916871A (ja) * | 1982-07-20 | 1984-01-28 | Shionogi & Co Ltd | スルホンアミド系ベンズアミド類 |
| PH23565A (en) * | 1986-09-05 | 1989-08-25 | Sumitomo Chemical Co | Novel pyrimidinylpyrimidine derivatives and a plant disease protectant containing them as the active ingredient |
| JPH01114005A (ja) | 1987-10-28 | 1989-05-02 | Fuji Elelctrochem Co Ltd | 永久磁石粉体の造粒方法 |
| AU1555897A (en) * | 1996-02-02 | 1997-08-22 | Ihara Chemical Industry Co. Ltd. | Pyridone derivatives and herbicides |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| WO2001085172A1 (en) | 2000-05-10 | 2001-11-15 | Smithkline Beecham Corporation | Novel anti-infectives |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| CA2577528A1 (en) * | 2004-08-23 | 2006-03-02 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CA2623728A1 (en) * | 2005-09-30 | 2007-04-12 | F. Hoffmann-La Roche Ag | Nnrt inhibitors |
| WO2008009078A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| WO2008082488A1 (en) | 2006-12-22 | 2008-07-10 | Schering Corporation | 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| US8557848B2 (en) | 2006-12-22 | 2013-10-15 | Merck Sharp & Dohme Corp. | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections |
| WO2008104473A2 (en) | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
| CN101918369B (zh) | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| TWI401023B (zh) * | 2008-02-06 | 2013-07-11 | Du Pont | 中離子農藥 |
| MX2011010047A (es) | 2009-03-25 | 2011-10-11 | Abbott Lab | Compuestos antivirales y usos de los mismos. |
| SG174214A1 (en) | 2009-03-25 | 2011-10-28 | Abbott Lab | Antiviral compounds and uses thereof |
| JP2012524752A (ja) * | 2009-04-25 | 2012-10-18 | エフ．ホフマン−ラ ロシュ アーゲー | 複素環式抗ウイルス化合物 |
| MX2011012541A (es) * | 2009-06-24 | 2012-08-03 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
| CA2768924A1 (en) * | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CA2780526A1 (en) * | 2009-12-14 | 2011-06-23 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
-
2009
- 2009-12-14 CN CN2009801516927A patent/CN102256968A/zh active Pending
- 2009-12-14 SG SG2011045903A patent/SG172778A1/en unknown
- 2009-12-14 WO PCT/EP2009/067028 patent/WO2010072598A1/en not_active Ceased
- 2009-12-14 MX MX2011006647A patent/MX2011006647A/es not_active Application Discontinuation
- 2009-12-14 EP EP09768529A patent/EP2379534A1/en not_active Withdrawn
- 2009-12-14 KR KR1020117016526A patent/KR20110094352A/ko not_active Ceased
- 2009-12-14 JP JP2011542761A patent/JP2012513434A/ja active Pending
- 2009-12-14 BR BRPI0924121A patent/BRPI0924121A2/pt not_active IP Right Cessation
- 2009-12-14 AU AU2009331660A patent/AU2009331660A1/en not_active Abandoned
- 2009-12-14 CA CA2745865A patent/CA2745865A1/en not_active Abandoned
- 2009-12-14 US US12/636,999 patent/US8178547B2/en not_active Expired - Fee Related
- 2009-12-21 AR ARP090105002A patent/AR074819A1/es unknown
- 2009-12-21 TW TW098143976A patent/TW201034671A/zh unknown
-
2011
- 2011-05-24 IL IL213102A patent/IL213102A0/en unknown
- 2011-06-10 ZA ZA2011/04362A patent/ZA201104362B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201034671A (en) | 2010-10-01 |
| CN102256968A (zh) | 2011-11-23 |
| CA2745865A1 (en) | 2010-07-01 |
| US20100158860A1 (en) | 2010-06-24 |
| AR074819A1 (es) | 2011-02-16 |
| IL213102A0 (en) | 2011-07-31 |
| KR20110094352A (ko) | 2011-08-23 |
| WO2010072598A1 (en) | 2010-07-01 |
| JP2012513434A (ja) | 2012-06-14 |
| ZA201104362B (en) | 2012-02-29 |
| US8178547B2 (en) | 2012-05-15 |
| MX2011006647A (es) | 2011-07-12 |
| AU2009331660A1 (en) | 2011-06-30 |
| SG172778A1 (en) | 2011-08-29 |
| EP2379534A1 (en) | 2011-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0916233A2 (pt) | compostos heterocíclicos antivirais | |
| BR112012005616A2 (pt) | compostos antivirais heterocíclicos | |
| BRPI1010852A2 (pt) | compostos antivirais heterocíclicos | |
| ATE539070T1 (de) | Heterozyklische antivirale verbindungen | |
| SMT201600351B (it) | Composti antivirali | |
| BRPI0821349A2 (pt) | compostos antivirais heterocíclicos | |
| BRPI0924121A2 (pt) | compostos antivirais heterocíclicos | |
| BRPI0906705A2 (pt) | Composto heterocíclicos | |
| DK2288375T3 (da) | Pegylerede insulin-lispro-forbindelser | |
| BRPI0920707A2 (pt) | compostos | |
| DK2242759T3 (da) | Forbindelser | |
| DK2308877T3 (da) | Imidazopyridin-2-on-derivater | |
| BRPI0907435A2 (pt) | Derivados de 5-flúor pirimidina | |
| EP2269990A4 (en) | Heterocyclic compound | |
| ATE502948T1 (de) | Substituierte bicyclolactamverbindungen | |
| EP2266989A4 (en) | HETEROCYCLIC DERIVATIVES | |
| BRPI1016266A2 (pt) | compostos antivirais heterocíclicos | |
| ATE484507T1 (de) | Heterocyclische spiroverbindungen | |
| DK2323972T3 (da) | C7-fluor-substituerede tetracylinforbindelser | |
| DK2297162T3 (da) | Forbindelser | |
| DK2275414T3 (da) | Cyclopentylacrylamidderivat | |
| BRPI0920496A2 (pt) | derivados substituídos de pirimidina etriazina | |
| ATE545635T1 (de) | Substituierte n-oxidpyrazinderivate | |
| EP2295406A4 (en) | HETEROCYCLIC CONNECTION | |
| HRP20150932T1 (xx) | Heterocikliäśki spojevi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |